Xilio Development Inc (XLO)
Xilio Development Inc. is a clinical-stage biotechnology company focused on discovering and developing tumor-activated immuno-oncology therapies. Its pipeline includes XTX101, an Fc-enhanced, tumor-activated anti-CTLA-4 monoclonal antibody in Phase 2 testing for advanced solid tumors. The company is also advancing cytokine programs such as XTX202, a tumor-activated, beta-gamma biased IL-2 candidate in Phase 2 studies, and XTX301, an engineered, tumor-activated IL-12 molecule in Phase 1 development. Founded in 2016, Xilio is headquartered in Waltham, Massachusetts, and its common stock is listed on NASDAQ under the symbol XLO.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-XLO
|
—
|
—
|
—
|
$20
|
129.8% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-1.7x
|
0.7x
|
1.0x
|
51.273 M
|
-91.614 M
|
11.5%
|
62.7%
|
-1.7
|
—
|
183.3%
|
